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Introduction
The human leukocyte antigen B (HLA-B) gene is a
member of the major histocompatibility complex (MHC),
a region of the human genome located on chromosome 6.
The MHC [also known as the human leukocyte antigen
(HLA) complex] includes three subregions, designated
as class I, class II, and class III. Each of these subregions
contains a variety of genes that mainly code for proteins
involved in the immune system. HLA-B is part of the
class I group, along with HLA-A and HLA-C, all three of
which code for their eponymous proteins [1]. Class II
genes include HLA-DR, HLA-DP, and HLA-DQ [2],
and class III genes include complement components
and cytokines such as complement factor B (CFB) and
members of the tumor necrosis factor (TNF) family [1,3].
The MHC is a large region of the genome and contains
many other genes besides the ones listed above; please
see Horton et al. [1] for more details. The HLA genes are
important within the field of pharmacogenetics: varia-
tions within these genes have been associated with
severe drug reactions as well as changes in how well a
patient responds to a drug.
The HLA-B protein and the other class I group members
are cell-surface molecules responsible for the presenta-
tion of endogenous peptides to CD8+ T cells and exist
on almost all nucleated cells. This is in contrast to class II
molecules, which display exogenous peptides to CD4+
T cells, and are present only on antigen-presenting cells
such as macrophages or dendritic cells [2,4]. This pre-
sentation of peptides to T cells aids in the recognition of
pathogens [2]. As a class I molecule, most of the peptides
that HLA-B presents come from the normal breakdown
of host cellular proteins and are recognized by the
immune system as such (i.e. ‘self’ peptides). However,
when a cell becomes infected by a pathogen, the proteins
presented will be from the pathogen and recognized as
foreign or ‘nonself’. T-cell antigen receptors on CD8+
cytotoxic T cells are responsible for this recognition and
will stimulate an immune reaction that destroys the
cell [5].
Class I molecules are expressed in a codominant manner,
and humans inherit a set of HLA-A, B, and C genes from
each parent. Therefore, given allelic variations within
these genes, up to six different class I molecules can
be expressed on a cell surface. HLA-A, B, and C are
heterodimers consisting of an α chain, encoded by
their respective genes, and a protein known as
β2-microglobulin, which is encoded on chromosome 15.
The α chain of HLA-B has four domains: one cyto-
plasmic, one transmembrane, one that binds to CD8+
cytotoxic T cells, and one that makes up a peptide-
binding groove, where the presented peptide is nestled
[5]. This peptide-binding region of the gene is highly
polymorphic, and allelic differences between class I
genes are often because of variations within this region
[2,5]. Indeed, allelic variants of class I genes can differ
from one another by up to 20 amino acids. Peptides bind
to the groove through interaction with specific amino acid
residues; thus, any amino acid changes because of allelic
variation may affect the peptide-binding specificity of a
class I molecule [5] (class II molecules have more flex-
ibility in peptide-binding; see Janeway et al. [5]). The
type of extensive polymorphism seen in HLA genes
allows a wide variety of peptides to be presented, and
likely evolved to combat pathogens effectively [5]. In
addition to affecting the peptides capable of being
presented, allelic variants in the HLA-B gene have also
been associated with susceptibility and resistance to
numerous diseases as well as adverse reactions to a wide
range of pharmaceuticals. This makes HLA-B highly
relevant to pharmacogenetic research. This Very
Important Pharmacogene summary onHLA-B is available
with interactive links to genetic variants and drugs on the
PharmGKB website at http://www.pharmgkb.org/gene/
PA35056.
HLA-B allele frequencies and nomenclature
Because of the highly polymorphic nature of class I
genes, a large number of HLA-B alleles have been
identified. Information on the frequencies of over 2800
HLA-B alleles in populations worldwide can be found at
The Allele Frequency Net Database (http://www.allele
frequencies.net/) [6]; allele frequencies for specific poly-
morphisms will be discussed within relevant sections of
this review. Systematic nomenclature for these alleles is
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invaluable, given their quantity. The HLA nomenclature
committee has provided a detailed nomenclature to this
end, and comprehensive information on the allele nam-
ing process can be found at their website at http://hla.
alleles.org [7]. Briefly, all HLA alleles receive at least a
four-digit name consisting of two sets of two digits
separated by a colon, such as HLA-B*57:01. The first set
of digits before the colon describes the type, typically the
antigen designation used to describe the HLA alleles
before genetic sequencing. The second set of digits
indicates the specific allele, numerically ordered on the
basis of when the DNA sequence was discovered; this set
of digits describes nonsynonymous substitutions only [7,
8]. This paper will only refer to the first one or two sets of
digits. However, longer names, up to four sets of digits
separated by colons and possibly a letter suffix, can be
assigned if more detail is necessary, such as the type or
the location of nucleotide substitution (e.g. synonymous
or intronic) or resultant protein expression (e.g. null
protein or cytoplasmic protein); for more information on
this process, please refer to the HLA nomenclature
website (http://hla.alleles.org).
HLA-B and disease associations
A number of HLA-B alleles or allele groups have been
associated with susceptibility or resistance to particular
diseases. These include HLA-B*53 and resistance to
malaria [9,10], HLA-B*51, and susceptibility to the
inflammatory condition Beçhet’s disease [11,12], and
HLA-B*46, and increased risk of Graves’ disease, an
autoimmune disorder [13]. Two particularly strong dis-
ease associations are HLA-B*57 and HIV long-term
nonprogression, and HLA-B*27 and ankylosing
spondylitis (AS).
HLA-B*57 and HIV long-term nonprogression
Without treatment, almost all patients infected with HIV
will ultimately progress to AIDS. However, a small per-
centage of patients do not advance, even long after the
median progression time. These patients are referred to
as long-term nonprogressors or ‘elite controllers’, and
HLA-B*57 alleles, particularly *57:01 and *57:03, are
highly enriched in this group of individuals [14–21].
Although this association is well known, the mechanism
by which it occurs remains unclear. Kosmrlj and collea-
gues used computer algorithms to predict that less than
half the number of unique peptides (derived from the
human proteome) bound to the HLA-B*57:01 protein
compared with HLA-B*07:01 (a non-HIV-protective
form of the molecule). The authors suggested that this
affected repertoire development, leading to T cells that
had been exposed to fewer self-peptides. This in turn
may lead to a higher frequency of T cells that recognize
viral peptides, such as those from HIV, as well as T cells
that are more cross-reactive toward mutant epitopes.
These qualities would enable the T cells to better control
the HIV infection, keeping the viral load in check and
thereby making the development of AIDS unlikely [16].
HLA-B*27 and ankylosing spondylitis
AS is a chronic inflammatory rheumatic disease, affecting
mainly the axial skeleton and the sacroiliac joints. It leads
to inflammatory back pain, as well as other clinical fea-
tures including enthesitis and anterior uveitis [22]. The
presence of HLA-B*27 leads to the highest risk for AS,
and this form of HLA-B is found in over 90% of AS
patients with European ancestry. However, only 1–5% of
HLA-B*27 individuals will go on to develop AS, and not
all alleles of HLA-B*27 are associated with its develop-
ment. AlthoughHLA-B*27:05, *27:02, *27:04, and *27:07
do confer risk, other types such as *27:06 and *27:09 do
not appear to be associated with the disease [23]. As with
HIV and HLA-B*57:01, the mechanism behind this
association is unclear, although multiple theories have
attempted to explain the relationship. Several of these
theories are summarized in a review by McHugh and
Bowness [24], including the arthritogenic peptide
hypothesis, which suggests that HLA-B*27 binds parti-
cular peptides that give rise to a cytotoxic T-cell
response, the misfolding and unfolded protein response
hypothesis, which suggests that the accumulation of
abnormally folded HLA-B*27 molecules leads to an
inflammatory response, and the free heavy chain and
homodimer hypothesis, where AS results from the
immune recognition of monomeric or dimeric
β2-microglobulin-free and peptide-free HLA-B*27
molecules [24]. Recent GWAS analyses have identified a
number of non-MHC genes associated with AS sus-
ceptibility; these genes may help explain the mechanism
of AS pathogenesis. For example, multiple genes within
the interleukin-23 (IL-23) proinflammatory cytokine
pathway were associated with AS, indicating that this
may be a core immunological pathway underlying disease
development. In addition, multiple aminopeptidase
genes, such as ERAP1 and ERAP2, have been associated
with AS. The protein products of these genes are
involved in peptide trimming before HLA class I binding
and presentation, suggesting that HLA-B*27 may be
involved in disease development through the aberrant
trimming or presentation of peptides [25–28].
HLA-B pharmacogenetics
HLA-B alleles have been associated with reactions to a
large number of different drugs. Some of these associa-
tions have been well studied, such as HLA-B*57:01 and
abacavir hypersensitivity, HLA-B*58:01 and allopurinol-
induced severe cutaneous adverse reactions (SCARs),
and HLA-B*15:02 and carbamazepine (CBZ)-induced
Stevens–Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN). Other associations that are not as
widely studied, but still show significant results include
HLA-B*57:01 and flucloxacillin-induced liver injury and
HLA-B*15:02 and phenytoin-induced SJS and TEN.
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A list of the HLA-B alleles and pharmacogenetic asso-
ciations discussed in this review (along with their positive
and negative predictive values, if available) can be found
in Table 1. For the alleles presented in this paper, there
is no difference in phenotype depending on whether one
or two HLA-B alleles are present, and therefore, the
pharmacogenetic studies discussed only consider whe-
ther an individual has the allele or not. Consequently, in
the tables throughout this review, the ‘prevalence’ of an
HLA-B allele refers to how many patients carry that allele
and not the frequency of the allele in the population.
Some studies do use allele frequencies in their statistical
analyses, and these cases are noted within the tables.
Many other HLA-B alleles besides the ones discussed
in this paper have shown associations with various
drug phenotypes. A table of all the HLA-B allele and
drug phenotype associations currently annotated by
PharmGKB can be found on the website at http://www.
pharmgkb.org/gene/PA35056.
HLA-B testing
Several options exist for determining whether a patient
carries a particular HLA-B allele. One is by direct
sequencing of the gene, and assignment of a star allele
after checking the sequence against known HLA-B
alleles. Although this method provides high-resolution
genotyping and is the most accurate, it is both time-
consuming and expensive and is not used widely [8]. An
alternative and commonly used approach is genotyping,
where the sequence variants known to define a particular
HLA-B allele are detected using PCR primers specific for
each variant [8]. Quality assurance studies carried out on
the accuracy of HLA-B*57:01 testing using sequence-
specific primer PCR across multiple laboratories have
shown very high sensitivity and specificity, indicating
that laboratories using this method appear to be offering
effective screening for the allele [35]. Another method
that offers cost-effective, rapid, and sensitive screening
for HLA-B*57:01 or HLA-B*58:01 is flow cytometry.
HLA-B*57:01 and HLA-B*58:01 belong to a serological
group known as HLA-B17. B17 monoclonal antibodies
can be used to identify individuals who carry the HLA-
B17 serotype, and these individuals can then undergo
further DNA typing to determine whether they carry the
*57:01 or *58:01 risk alleles. As B17 is normally present in
less than 10% of the population, assaying for the presence
of B17 first allows greater than 90% of a patient popula-
tion to be eliminated from unnecessary HLA testing
[36–38].
It is also possible to test for the presence of an HLA-B
allele by genotyping for one or more single nucleotide
polymorphisms (SNPs) nearby in linkage disequilibrium
with that allele. However, linkage disequilibrium can
vary across populations, and this method may have lower
accuracy [8,39]. The HCP5 SNP rs2395029 has been
suggested as a potential marker for abacavir-induced
hypersensitivity as the variant allele has shown strong
linkage disequilibrium with *57:01 [40–43]. However, it
is not in complete concordance with *57:01 [44,45], and
individuals with the *57:01 allele, but not the rs2395029
variant allele [44–46] as well as individuals with the
rs2395029 variant allele, but not the *57:01 allele [40,41,
44,45] have been noted. This type of incomplete con-
cordance could result in the denial of abacavir to indivi-
duals who are not at risk for a hypersensitivity reaction
(HSR) or administration of abacavir to individuals who
are at risk for an HSR [8,46]. In addition, the studies
showing strong linkage between *57:01 and rs2395029
have been carried out in populations of mainly Caucasian
or Hispanic descent; the strength of the linkage between
the alleles has not been confirmed in large African or
Asian populations [8]. Several studies have noted that
caution should be exercised when using rs2395029 as a
surrogate marker for HLA-B*57:01 [8,31,47]. However,
because of the inexpensive and straightforward nature of
this screening method, some laboratories do choose to
perform SNP testing over allele-specific PCR [8].
It is important to note that currently, the high level of
polymorphism within the HLA genes makes HLA geno-
typing at a high resolution challenging [48–50]. The
present sequencing methods can result in ambiguous
typing results with an inability to resolve phase [48,49].
In addition, different alleles may share similar sequences
within the sequenced region [50], and defining poly-
morphisms may lie outside the amplified region [48,49].
These issues may be resolved through next-generation
Table 1 List of HLA-B alleles and their associated drug phenotypes
HLA-B risk allele Drug Phenotype References PPV (%) NPV (%) References
*57:01 Abacavir
Flucloxacillin
Hypersensitivity reaction
Drug-induced liver injury
See Table 2
Daly et al. [30]
55 100 Mallal and colleagues [29,31]
*58:01 Allopurinol SCARs, MPE See Table 3 1.5 100 Tassaneeyakul et al. [32]
*15:02 Carbamazepine
Phenytoin
SJS/TEN
SJS/TEN
See Table 4
See Table 5
1.8
33a
100
100a
Yip et al. [33]
Tassaneeyakul et al. [34]
The phenotypes listed for each drug are more likely to occur in patients who carry the associated allele. For example, carriers of *57:01 who are administered abacavir have
an increased chance of a hypersensitivity reaction compared with noncarriers. When available, positive and negative predictive values are also shown. An interactive
version of this table is available online at http://www.pharmgkb.org/gene/PA35056.
HLA, human leukocyte antigen; MPE, maculopapular eruption; NPV, negative predictive value; PPV, positive predictive value; SCARs, severe cutaneous adverse reactions;
SJS/TEN, Stevens–Johnson Syndrome/toxic epidermal necrolysis.
aFor phenytoin-induced SJS only.
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sequencing, which allows for clonal amplification and
massively parallel sequencing. These two properties
provide phase information and the ability to sequence
more and larger regions of genes, including intronic
regions [48,49].
A list of commercially available genetic tests for various
HLA-B alleles can be found on PharmGKB at http://www.
pharmgkb.org/views/viewGeneticTests.action; a more com-
prehensive list can be found at the Genetic Testing
Registry (http://www.ncbi.nlm.nih.gov/gtr/). As HLA-B
expression is codominant, HLA-B genotyping results
are either ‘positive’, with the * allele being present in one
or both copies of the gene, or ‘negative’, where no copies
of the allele are present; there is no intermediate phe-
notype [8].
Important variants
HLA-B*57:01
Abacavir
In addition to being enriched in HIV long-term non-
progressors, the *57:01 allele is also associated strongly
and independently with the development of an abacavir
HSR. Abacavir is a nucleoside reverse transcriptase
inhibitor used for the treatment of HIV. It is generally
well tolerated, and common side effects include nausea,
headache, and diarrhea [51]. However, ∼ 5–8% of
patients experience an HSR within the first 6 weeks of
treatment [8]. Symptoms of an HSR include at least two
of the following: fever, rash, cough, gastrointestinal
symptoms (e.g. nausea, vomiting, abdominal pain), dys-
pnean and fatigue [8]. These symptoms worsen with
continued treatment, but typically improve within 24 h
after discontinuation. However, drug rechallenge after
discontinuation of abacavir because of an HSR can result
in symptom recurrence within a matter of hours and
potentially life-threatening allergic reactions [52,53]. An
overview of abacavir and *57:01 pharmacogenetic studies
can be found in Table 2.
In 2002, two separate research groups published the first
evidence that HLA-B*57:01 was present in a significantly
higher percentage of patients showing an abacavir HSR
compared with patients with no reaction. These studies
were carried out in North American [54] and Australian
[53] populations, and both included 200 participants.
This association was subsequently confirmed by another
study within a UK population of 64 patients [55].
However, these three studies were all carried out using
predominantly Caucasian men, limiting their scope.
Despite this limitation, several clinics began imple-
menting prospective screening of these alleles with suc-
cess [59–61]. A later study recognized the significance of
the allele in White female and Hispanic populations, but
found no significant associations for the Black population
from this study [62]. This was likely because of the lower
number of Black patients in the study and the fact that
Black populations tend to have a lower carriage rate of
the allele [56,62] – African populations often have *57:01
allele frequencies of less than 2.5%, in contrast to
European populations, who often have *57:01 fre-
quencies of 6–7% [8]. Indeed, a study in Ugandan
patients failed to find the *57:01 allele in either patients
with an abacavir HSR or tolerant controls [58].
In 2007, a study known as SHAPE (which included a
similar number of White and Black participants) found
that fewer cases of abacavir HSRs were found among
Black patients. However, 100% of both White and Black
patients who had immunologically confirmed HSRs were
positive for the HLA-B*57:01 allele [56]. This suggested
that although immunologically confirmed HSRs are rare
among Black populations because of the reduced fre-
quency of *57:01, the allele has the same clinical impli-
cations in both populations [56]. A definitive association
between *57:01 and abacavir HSRs emerged in 2008
with the results of the PREDICT-1 study, a double-
blind, prospective, randomized study with 1956 patients
from 19 countries. Patients were observed for 6 weeks
and divided into two categories: those who underwent
screening for the HLA-B*57:01 allele and were excluded
from treatment with abacavir if they tested positive and
those who underwent standard care without any screen-
ing. Abacavir HSRs were immunologically confirmed
with skin patch testing. The results of the study showed
that screening eliminated immunologically confirmed
HSRs – 0% of the patients screened had an HSR,
whereas 2.7% of the control population did. This gave
the screening a negative predictive value of 100% [29].
The positive predictive value of HLA-B*57:01 for
abacavir-induced HSRs is typically cited as 55%, imply-
ing that around half of all patients who are HLA-B*57:01
positive will not develop an abacavir HSR [31,63,64].
This indicates that other genes and environmental factors
are likely involved in the development of an abacavir-
induced HSR. Research in this area has been scarce, but
several studies have suggested a member of the 70 kDa
heat shock protein (HSP70) family as a potential factor
[65–67].
This body of evidence led the Food and Drug
Administration (FDA) to implement a boxed warning in
2008, detailing the risk of an HSR for abacavir-treated
patients with the HLA-B*57:01 allele. The FDA also
recommended that all patients be screened before being
treated, and to not use abacavir in HLA-B*57:01-positive
individuals [68]. The European Medicines Agency [69],
and therapeutic guidelines from the Clinical
Pharmacogenetics Implementation Consortium (CPIC)
[8] and the Dutch Pharmacogenetics Working Group [70]
also recommend genotyping for this allele before begin-
ning abacavir treatment.
The HLA-B protein exerts no direct effect on abacavir
pharmacokinetics or pharmacodynamics, and it is still
unclear how the HLA-B*57:01 allele affects susceptibility
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Table 2 Summary of abacavir and *57:01 pharmacogenetic studies
P-values and ORs listed pertain to the risk for an abacavir hypersensitivity reaction (HSR) in patients carrying the *57:01 allele compared with noncarriers. P-values and
ORs were calculated by comparing the frequency of *57:01 in patients who developed an HSR compared with the frequency in abacavir-tolerant controls. The prevalence
of *57:01 is listed for patients who developed an HSR (case) and in those who were abacavir-tolerant (control). An interactive version of this table is available online at
http://www.pharmgkb.org/haplotype/PA165956565, and is updated as new results come to our attention.
CI, confidence interval; HLA, human leukocyte antigen; OR, odds ratio.
aUnspecified remaining races.
bData using a ‘standard’ case definition: cases of hypersensitivity were either ‘definite/probable’ or ‘possible’. Results differed, but were still significant for White and
Hispanic patients (and still nonsignificant for Black patients) using a ‘restrictive’ case definition – only cases that were ‘definite/probable’. For ‘restrictive’ case definition
data, please refer to the paper directly.
cImmunologically confirmed HSRs. For clinically confirmed HSR data, please refer to the paper directly.
dIncluding 4.7% Indo-Asian, 3.1% Hispanic, 2% Metis and 2.2% oriental or unknown.
eClinically confirmed HSRs.
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to drug hypersensitivity. Several hypotheses exist. One is
the hapten concept, which suggests that small com-
pounds such as drugs (haptens) bind to the peptides
bound to immune receptors such as HLA-B, causing T
cells to react and stimulate an immune reaction [71].
Another is the p-i concept (pharmacological interactions
with immune receptors), which proposes that drugs bind
directly and reversibly to immune receptors, stimulating
an immune reaction [71]. Recent evidence seems to
support an alternative hypothesis. Two studies, both
published in 2012, found that abacavir can bind non-
covalently and with specificity to the F pocket of the
peptide-binding groove of HLA-B*57:01 [72,73].
Because of the amino acid residues unique to the *57:01
protein, abacavir can bind only to this particular form of
HLA-B. The binding of abacavir to HLA-B*57:01 is
believed to alter the shape and chemistry of the antigen-
binding cleft, and consequently, the repertoire of pep-
tides which can bind the molecule. Indeed, both of these
papers, as well as an additional paper by Norcross and
colleagues, all identified specific changes in the peptides
presented by HLA-B*57:01 in the presence of abacavir
compared with HLA-B*57:01 in the absence of the drug
[72–74]. As T cells are trained to be tolerant to a parti-
cular repertoire of peptides during their development in
the thymus, the alteration in the peptides that can be
presented may mean that these new peptides are per-
ceived as foreign. This change would stimulate CD8+
T-cell production and response, and would manifest as an
abacavir HSR [72,73]. Indeed, CD8+ T cells are abun-
dant in skin biopsies of patients who present with a rash
during an abacavir HSR [75].
Flucloxacillin
HLA-B*57:01 is also associated with flucloxacillin drug-
induced liver injury (DILI). Flucloxacillin is a semisyn-
thetic penicillin, used widely across Europe and Australia
for staphylococcal infection [30,76]. However, it is also
associated with the development of cholestatic hepatitis,
with risk factors being female sex, age older than
55 years, and treatment duration of longer than 2 weeks
[76]. A genome-wide association study found that a
marker in complete linkage disequilibrium with HLA-
B*57:01 was also strongly associated with flucloxacillin
DILI. Further analysis found that patients with this allele
had an 80-fold increased risk of developing DILI com-
pared with those without the allele [30]. However, flu-
cloxacillin DILI is a very rare condition, with an
estimated prevalence of only 8.5 out of every 100 000
patients. In addition, the positive predictive value of
*57:01 for DILI is only 0.12%, meaning that the majority
of patients with *57:01 will not develop flucoloxacillin-
induced DILI. Indeed, this positive predictive value
indicates that almost 14 000 white patients would need to
be tested for *57:01 and excluded from receiving the
drug to prevent one case of DILI; in non-white or mixed
populations, this number could be higher [77]. Given the
low positive predictive value and the high number nee-
ded to test to prevent one case, pretreatment screening
implementation in the clinic is likely not feasible at this
time. In their discussion of flucloxacillin HLA-B*57:01
screening, Phillips and Mallal [77] suggest that a more
practical approach would be to carefully monitor patients
receiving flucloxacillin and to consider their HLA-
B*57:01 genotype only if there is biochemical evidence
for hepatitis, at which point the drug can be stopped. It is
uncertain how the presence of the *57:01 allele leads to
an increased risk for flucloxacillin-induced DILI.
However, it does not appear to be through the same
mechanism as *57:01 and abacavir hypersensitivity:
Wuillemin et al. [78] found that in the presence of the
HLA-B*57:01 molecule, flucloxacillin stimulated T cells
(including CD8+ T cells) according to the p-i concept.
In a later study, Wuillemin et al. [79] also showed that
DILI might be caused by the infiltration of cytotoxic
CD8+ and CD3+ T cells into the liver. Consideration
of the results from both studies of Wuillemin and col-
leagues provides a possible explanation for the connec-
tion between *57:01 and DILI.
HLA-B*58:01
Allopurinol
The HLA-B*58:01 allele is associated strongly with
allopurinol-induced SCARs, which include hypersensi-
tivity syndrome (HSS) and SJS/TEN [80]. Allopurinol is
mainly used for conditions associated with hyperur-
icemia, such as gout and tumor lysis syndrome [81]. The
drug works by inhibiting the enzyme xanthine oxidase,
which is responsible for the conversion of hypoxanthine
and xanthine into uric acid. In this manner, the drug
lowers the amount of uric acid created in the body [80,
82]. Most side effects from allopurinol are mild, with the
most common complaint being gastrointestinal upset [80,
82]. However, allopurinol has also been associated with
severe adverse reactions. SJS and TEN (or SJS/TEN
when referencing both) are two forms of the same con-
dition. Both involve severe mucocutaneous blistering and
epidermal detachment, and usually present 1–3 weeks
after treatment begins. SJS and TEN are distinguished
by the amount of skin detachment: SJS is classified as
1–10% detachment of body surface area (BSA), SJS and
TEN overlap as 10–30% of BSA, and TEN as greater
than 30% of BSA. Although the occurrence of these
symptoms is rare (only two patients per million per year),
SJS and TEN can be permanently disabling or even fatal.
The mortality rate correlates with the level of skin
detachment, ranging from a 1–5% mortality rate for SJS to
a 25–35% mortality rate for TEN [83,84]. In contrast to
SJS/TEN, HSS (also known as drug-induced hypersen-
sitivity syndrome or drug reaction with eosinophilia and
systemic symptoms) typically has organ involvement,
such as hepatitis or nephritis, in addition to fever and a
severe rash [85–87]. The risk of developing SCARs
during allopurinol treatment is 0.1–0.4% [80]. In some
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association studies with allopurinol-induced SCARs, only
the relationship with SJS/TEN is discussed and HSS is
not used as an associated phenotype.
The first association between HLA-B*58:01 and SCARs
emerged from a 2005 Taiwanese study on Han Chinese
patients, which found that 100% of the 51 patients
who developed allopurinol-induced SCARs had the
HLA-B*58:01 allele, whereas only 15% of the 135
allopurinol-tolerant patients carried the allele. This yiel-
ded an odds ratio of 580 for the development of SCARs
with this particular allele [85]. Follow-up studies in Thai,
Korean, Japanese, Han Chinese, and European popula-
tions also found significant results [32,88–95]. However,
differences exist between these ethnicities when con-
sidering the magnitude of risk for developing SCARs.
Although Han Chinese and Thai patients show excep-
tionally high odds ratios for developing SCARs,
European and Japanese *58:01 carriers show compara-
tively much lower risks for the development of SCAR
(Table 3). This disparity in odds ratios is likely because
of variations in *58:01 frequencies between ethnicities,
rather than a differing effect of the *58:01 allele
depending on ethnicity. Although the Han Chinese and
Thais tend to have *58:01 allele frequencies of around
8%, Europeans and Japanese have allele frequencies of
∼ 1.4 and 0.5%, respectively [6,32,92,94]. The *58:01
allele may also be associated with a more mild cutaneous
adverse drug reaction, maculopapular eruption (MPE),
which presents as a rash consisting of macules and
papules. Cao et al. [88] found that 100% of their Han
Chinese patients who developed an MPE while receiv-
ing allopurinol carried the *58:01 allele. In contrast, Lee
and colleagues found that none of their 12 patients who
presented with MPE carried the *58:01 allele, whereas
six out of 11 of their patients who developed SCARs did.
However, this may be because of the large presence of
Caucasians in their study, a population with a low *58:01
frequency. Eleven of the patients with MPE were
Caucasian, as were the five patients who developed
SCARs, but did not carry *58:01 [96]. Table 3 presents an
overview of allopurinol and *58:01 pharmacogenetic
studies, and indicates whether a study has analyzed
SCARs, SJS/TEN, HSS, or MPE.
Because of the strong associations observed between
*58:01 and allopurinol, the CPIC recommends genotyp-
ing before treatment with allopurinol and suggests that
the drug should be contraindicated in patients with one
or more *58:01 alleles [80]. The American College of
Rheumatology also recommends that *58:01 screening be
considered when assessing the risks of the drug, espe-
cially in populations with high frequencies of the allele,
such as the Han Chinese or Thais [101]. Unlike abacavir,
no clinical trials have been published that test whether
genotyping for the presence of HLA-B*58:01 can reduce
the number of SCAR or SJS/TEN cases in patients
treated with allopurinol. On the basis of data from Han
Chinese and Thai populations, the negative predictive
value of this allele for SJS/TEN development is 100%,
but the positive predictive value is only about 1.5% [80].
This indicates that most patients who carry the allele will
not develop SJS/TEN. Discovery of new genetic, or
nongenetic, factors that lead to SJS/TEN or SCAR
development may help increase the positive predictive
value. Studies on the mechanism of SCAR development
in HLA-B*58:01 carriers have been limited. A recent
study suggested that it is a metabolite of allopurinol,
oxypurinol, which causes the HSR in individuals with the
HLA-B*58:01 allele: oxypurinol was found to bind to the
F pocket of HLA-B*58:01 through the p-i mechanism
with a higher affinity compared with allopurinol [102].
HLA-B*15:02
Carbamazepine
HLA-B*15:02 is associated strongly with SJS/TEN in
patients taking CBZ, an anticonvulsant and mood-
stabilizing drug. Along with epilepsy and bipolar dis-
order, CBZ is also used to treat a variety of other condi-
tions, such as schizophrenia, trigeminal neuralgia, and
carpal tunnel syndrome [103]. As with *58:01, the allele
frequency of *15:02 varies worldwide. Han Chinese have
an average allele frequency of almost 6%, but this value
can range anywhere from 1.9 to 12.4% depending on the
population [6]. In addition, other Chinese populations,
such as the Bulang, can have an allele frequency of close
to 36% [104]. Thai and Malaysian populations also have
high *15:02 allele frequencies, with average allele fre-
quencies of close to 8%. In contrast, Koreans show a
frequency of 0.3%, Japanese a frequency of 0.1%, and
Caucasians a frequency of only 0.06% [6]. These per-
centages correlate with the number and strength of stu-
dies finding significant results linking *15:02 with the
development of SJS/TEN: studies in Caucasian [105
–107] and Japanese [93] patients have been limited and
have shown exclusively nonsignificant results. One study
in Koreans found a significant association when compar-
ing allele frequencies for SJS/TEN patients against
population controls, but no significant association when
comparing against CBZ-tolerant controls [108]. In con-
trast, studies in Han Chinese are numerous and show
very high odds ratios for CBZ-induced SJS/TEN [107,
109–114]. Studies in Indian [115], Thai [34,116,117],
Malaysian [118,119], and Singaporean [120,121] popula-
tions have also found significant associations. These
pharmacogenetic studies are summarized in Table 4. In
addition, three meta-analyses (not included in Table 4)
that combined studies with Chinese, Korean, Malaysian,
and Thai patients all found odds ratios of ∼ 80 for the
development of CBZ-induced SJS/TEN in patients car-
rying the *15:02 allele [126–128].
Because of the low frequency in Korean, Japanese, and
Caucasian populations, screening for exclusively *15:02
may not be sufficient from a global perspective. Other
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Table 3 Summary of allopurinol and *58:01 pharmacogenetic studies
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Table 3 (continued)
P-values and odds ratios (ORs) listed pertain to the risk for allopurinol-induced adverse reactions in patients carrying the *58:01 allele compared with noncarriers. P-values
and ORs were calculated by comparing the frequency of *58:01 in patients who developed adverse reactions to the frequency of *58:01 in allopurinol-tolerant controls or
in healthy population controls. The prevalence of *58:01 is listed for patients who developed adverse reactions (case) and in those who were allopurinol-tolerant (tolerant
control) or from a healthy population (population control). An interactive version of this table is available online at http://www.pharmgkb.org/haplotype/PA165956630, and
is updated as new results come to our attention.
cADRs, cutaneous adverse drug reactions; CI, confidence interval; HSS, hypersensitivity syndrome; MPE, maculopapular eruption; SCARs, severe cutaneous adverse
drug reactions; SJS/TEN, Stevens–Johnson Syndrome/toxic epidermal necrolysis.
aFour of the six patients with *58:01 were of Southeast Asian origin and two were Caucasian. All patients with SCARs but without *58:01 (i.e. the five remaining patients)
were Caucasian.
bOne patient was of Southeast Asian origin and the remaining patients were Caucasian.
cIncludes 27 Caucasian patients, and four non-Caucasian patients of Pakistani, Cuban, Indian, and Senegalese background; all four non-Caucasian patients carried the
*58:01 allele.
dControls were from Western Europe, but specific ethnic information was not provided; the majority of these controls were assumed to be Caucasian.
eCases were exclusively Caucasian.
fEthnicity of the controls was not specified.
gMPE and SCAR.
hAllele frequencies.
iBorn in Germany to Kenyan parents.
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Table 4 Summary of carbamazepine and *15:02 pharmacogenetic studies
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Table 4 (continued)
P-values and odds ratios (ORs) listed pertain to the risk for carbamazepine-induced Stevens–Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) in patients
carrying the *15:02 allele compared with noncarriers. P-values and ORs were calculated by comparing the frequency of *15:02 in patients who developed SJS/TEN to the
frequency in carbamazepine-tolerant controls or in healthy population controls. The prevalence of *15:02 is listed for patients who developed SJS/TEN (case) and in those
who were carbamazepine-tolerant (tolerant control) or from a healthy population (population control). An interactive version of this table is available online at http://www.
pharmgkb.org/haplotype/PA165954769, and is updated as new results come to our attention.
CI, confidence interval; NS, nonsignificant; SJS, Stevens–Johnson syndrome.
aCaucasian only.
bPediatrics. Multiple ethnicities included, please refer to the paper directly for more information.
cAll three case patients with the allele were of Asian ancestry, countries unspecified.
dThe one tolerant control with the allele was of Asian ancestry, country unspecified.
eFour patients with *15:02 were of Asian ancestry (Vietnam, China, Cambodia, and Reunion Island). The remaining eight patients without *15:02 were Caucasian
(Germany, France).
fFour Malaysian, two Chinese.
gSix Malaysian, two Chinese.
hPediatrics. Two Chinese, three Malaysian.
iPediatrics. Seven Chinese, two Malaysian, one Indian.
jTen Chinese, three Malaysian.
kTwenty Chinese, six Malaysian.
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alleles have shown significant relationships with SJS/TEN
within these ethnicities, such as HLA-B*07:02 [105] and
HLA-A*31:01 [107,129–131]. Several studies in Japanese,
Korean, and Han Chinese patients suggest that carriers of
the HLA-B*15:11 alleles [108,112,132] have an increased
risk of developing SCARs. The average allele frequencies
for *15:11 in Japanese and Korean populations are higher
than for *15:02, with values of 0.4–0.8% for the Japanese
and 1.6% for Koreans [6]. Both *15:02 and *15:11 are part
of the same HLA-B75 serotype [108,132], and the two
alleles share a 98.6% amino acid sequence homology [112].
Therefore, they may share similar structures that lead to
the triggering of an immune reaction when CBZ is admi-
nistered [112]. Studies on *07:02, *31:01, and *15:11 are
limited compared with those on *15:02, and research into
alleles beyond *15:02may help improve predictive genetic
testing for SJS/TEN.
Unlike other HLA-B alleles, the associations between
HLA-B*15:02 and CBZ are phenotype specific. Many of
the studies mentioned above ([105–107,111,113,117,119,
120,123,125,126]) also looked for associations with HSS,
as well as MPE. However, none of the studies found any
associations between *15:02 and CBZ-induced HSS or
MPE, indicating that the allele may be particular to the
development of SJS or TEN. One study has assessed the
link between *15:11 and CBZ-induced HSS, and found
no significant association [108]. In contrast, HLA-A*31:01
has shown strong associations with the development of
CBZ-induced HSS or MPE in European [106,107,130],
Han Chinese [107,123], Japanese [131], and Korean [108]
populations, as well as in a meta-analysis that included
patients of all four aforementioned ethnicities [126].
A 2011 study assessed the value of genotyping before
CBZ treatment, with close to 4500 Taiwanese individuals
of Han Chinese descent participating. The 367 patients
who were found to be positive for *15:02 were told not to
take the medication, whereas the remaining 4120 took
the drug as normal. Because of ethical considerations,
historical incidences of SJS/TEN were used as a control.
Although no cases of SJS/TEN occurred in the study,
historical data estimations found that 10 cases of
SJS/TEN would have likely appeared in the study
cohort, a significant difference [133]. Although those of
Caucasian ethnicity do tend to have lower frequencies of
the *15:02 allele, genotyping before treatment is still
useful for these individuals as they may be unaware of
Asian ancestry or fail to alert their doctor to their heritage.
At this time, the US FDA recommends genotyping for
*15:02 before treatment with CBZ in all Asian popula-
tions, although it does not make recommendations for
patients of other ethnicities [134]. The negative pre-
dictive value of this allele for patients in Taiwan is sug-
gested to be 100% and the positive predictive value is
suggested to be 7.7% [134]. This low positive predictive
value implies that additional genetic or nongenetic fac-
tors likely play a role in the development of SJS/TEN in
patients taking CBZ. Despite the low positive predictive
value, it may be advisable to avoid the drug in *15:02-
positive patients, given that there are effective alter-
natives to CBZ [129,134]. Indeed, both CPIC and the
Canadian Pharmacogenomics Network for Drug Safety
recommend that a different agent be used if a patient is
found to be a carrier of the *15:02 allele because of a
strong increased risk for SJS/TEN [39,129].
The mechanism of CBZ-induced SJS/TEN is still
unclear. In a recent study, Wei and colleagues found that
peptide-loaded HLA-B*15:02 presented CBZ to cyto-
toxic T lymphocytes without any previous processing or
drug metabolism. Only HLA-B*15:02 could bind CBZ,
as opposed to HLA-B*15:01, *15:03, *40:01, or *51:01.
Endogenous peptides already loaded onto the molecule
were found to be required before CBZ could be pre-
sented [135]. The authors suggested that the binding of
CBZ to HLA-B*15:02 activates and induces clonal
expansion of cytotoxic (CD8+ ) T lymphocytes, eliciting
a severe immune reaction that leads to SJS or TEN [135].
The skin reaction observed in cases of SJS or TEN are
believed to be because of CD8+ T lymphocytes, which
are found in abundance in skin blister cells of patients
with SJS/TEN, and are believed to release cytotoxic
proteins that induce keratinocyte apoptosis [135–137].
One of the studies that looked at the mechanism of
abacavir-induced HSR also found that CBZ binds to
HLA-B*15:02, but no mention was made on whether
loaded endogenous peptides are necessary. However, the
authors noted that there was a repertoire shift in the
peptides bound to HLA-B*15:02 in the presence of CBZ,
albeit at a smaller magnitude than that of peptides bound
to *57:01 in the presence of abacavir. This change could
lead to an immune reaction by the same mechanism
suggested for an abacavir-induced HSR [72]. Further
studies in this area should help elucidate the precise
manner in which the *15:02 allele affects the develop-
ment of SJS/TEN in patients taking CBZ.
Phenytoin and other antiepileptics
*15:02 is also associated with SJS/TEN in patients taking
phenytoin, another antiepileptic; pharmacogenetic results
are presented in Table 5. Studies linking *15:02 with
SJS/TEN include four in Han Chinese patients [124,138
–140] and one in Thai patients limited only to SJS cases
[117]. In addition, a meta-analysis of four studies found a
significant association between *15:02 and phenytoin-
induced SJS/TEN [128]. Although these studies have
shown statistically strong results, they have been limited
in number and population size. One study in Thai chil-
dren found no link between *15:02 and phenytoin-
induced SCARs [141]. Variations within the CYP2C9
gene have also shown associations with phenytoin-related
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adverse reactions. Phenytoin is primarily metabolized to
its inactive form by CYP2C9, and alleles that result in
decreased enzymatic activity, specifically CYP2C9*2 and
*3, have been linked with increased phenytoin con-
centrations [142–145] and an increased risk for neurolo-
gical toxicities [146,147] and cutaneous adverse drug
reactions [140,148]. Consideration of both HLA-B*15:02
and CYP2C9*2 and *3 may be important in any future
clinical pretreatment screening programs.
Currently, the FDA recommends that physicians con-
sider the risks associated with SJS/TEN in patients tak-
ing phenytoin who have Asian ancestry and carry the
*15:02 allele, particularly in light of the evidence linking
*15:02 with CBZ-induced SJS/TEN [149]. Phenytoin,
CBZ, oxcarbazepine, phenobarbital, and lamotrigine are
all known as aromatic antiepileptic drugs (AEDs) because
of the presence of an aromatic ring in their structure –
symptoms of hypersensitivity were found to occur twice
as often in patients administered aromatic AEDs as
opposed to nonaromatic AEDs (e.g. levetiracetam or
topiramate) [150], suggesting that the presence of the
ring may be involved in the higher risk for adverse
reactions [151]. A recent study looking at children taking
CBZ, oxcarbazepine, or phenobarbital found that those
who developed SJS had a higher frequency of the
*15:02 allele compared with tolerant controls or healthy
population controls [152]. Wei et al. [135], in their study
on the mechanism by which *15:02 is associated with
CBZ-induced SJS/TEN, noted that oxcarbazepine,
which has a tricyclic ring structure similar to CBZ, was
also capable of binding with HLA-B*15:02, although not
as strongly as CBZ. However, studies linking HLA-
B*15:02 with oxcarbazepine-induced SJS or MPE have
shown mixed results [138,153–155]. Although no indivi-
dual studies have found significant associations between
*15:02 and lamotrigine-induced adverse reactions [124,
138,156,157], a meta-analysis of four studies did find a
significantly increased risk for SJS/TEN for patients
carrying *15:02 who receive lamotrigine [128].
Table 5 Summary of phenytoin and *15:02 pharmacogenetic studies
P-values and odds ratios (ORs) listed pertain to the risk for phenytoin-induced Stevens–Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) in patients carrying
the *15:02 allele compared with noncarriers. P-values and ORs were calculated by comparing the frequency of *15:02 for patients who developed SJS/TEN to the
frequency in phenytoin-tolerant controls. The prevalence of *15:02 is listed in patients who developed SJS/TEN (case) and in those who were phenytoin-tolerant (tolerant
control). An interactive version of this table is available online at http://www.pharmgkb.org/haplotype/PA165954769, and is updated as new results come to our attention.
CI, confidence interval; SCARs, severe cutaneous adverse drug reactions.
aCombined study results from Tassaneeyakul and colleagues [34,94,124].
bP-value for comparison in *15:02 frequencies between tolerant controls and combined cases.
cBonferroni-corrected P-value.
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Conclusion
The HLA-B gene has shown associations with a wide
range of diseases and adverse drug reactions. Despite
this, very little is understood about the mechanisms by
which variations in an immune system gene can affect
the propensity for certain pharmacological reactions or
particular illnesses. However, some progress has been
made in understanding the mechanisms behind abacavir
HSRs and CBZ-induced SJS/TEN, particularly in the
last couple years. Studies on abacavir HSRs have paved
the way for pharmacogenetic implementation within the
clinic: HLA-B*57:01 genotyping before abacavir treat-
ment is one of the key examples of pharmacogenetics
being used in routine medical practice. Given that HLA-
B*58:01 and *15:02 have also shown strong pharmaco-
genetic associations, these alleles may also be good can-
didates for clinical integration. HLA-B has been shown to
be an influential gene across many areas of medicine, and
future studies should improve our understanding of its
role in both disease and pharmacology.
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